Song Liu, PhD, MBA

Director of Biostatistics & Bioinformatics, CCSG Shared Resources
Vice Chair, Department of Biostatistics and Bioinformatics

Research Interests:

  • Translational Bioinformatics
  • Biomarker Discovery
  • Companion Diagnostics
  • Cancer Therapeutics
  • Precision Medicine
  • Immuno-Oncology

Biography

I was appointed to an Assistant Professor position at Roswell Park Comprehensive Cancer Center in 2009, an Associate Professor position in 2012, and a Full Professor position in 2016.

I completed the General Management Program at the Wharton School of Business, University of Pennsylvania in 2018 (WMP’18). I graduated with an MBA from the Massachusetts Institute of Technology Sloan School of Management in 2023.

Positions

Roswell Park Comprehensive Cancer Center

  • Professor of Oncology
  • Director of Biostatistics & Bioinformatics, CCSG Shared Resources
  • Vice Chair – Department of Biostatistics and Bioinformatics

Background

Education and Training

  • BS - 2002 - University of Science and Technology of China
  • PhD - 2006 - State University of New York at Buffalo
  • MBA - 2023 - MIT Sloan School of Management
  • Executive Education: General Management Program - Wharton School of Business, University of Pennsylvania

Fellowship

  • Post-doctoral Fellow - Howard Hughes Medical Institute (HHMI) at Columbia University

Professional Memberships

  • American Association for Cancer Research (AACR)
  • Society for Immunotherapy of Cancer (SITC)

Research Overview

Dr. Liu is a Professor of Oncology and Vice Chair of the Department of Biostatistics and Bioinformatics at Roswell Park Comprehensive Cancer Center. His research revolves around the development and application of computational methods to address biologically important and clinically significant questions in cancer prevention, diagnosis, and treatment.

Publications

  Full Publications list on PubMed

mTOR inhibition modulates vaccine-induced immune responses to generate memory T cells in patients with solid tumors. Withers HG, Matsuzaki J, Long M, Rosario SR, Chodon T, Tsuji T, Koya R, Yan L, Wang J, Keler T, Lele SB, Zsiros E, Lugade A, Hutson A, Blank S, Bhardwaj N, Shrikant P*, Liu S*, Odunsi K*. Journal for ImmunoTherapy of Cancer. 2025;13(3):e010408. 

Mutational landscape of triple-negative breast cancer in African American women. Yao S*, Wei L*, Hu Q*, Liu S*, Manojlovic Z, Fiorica PN, Long M, Zirpoli GR, Cai Q, Long J, Ping J, Barnard ME, Jin Y, Murakami M, Wang J, Zhu Q, Davis W, Chen J, Ondracek RP, Khoury T, Gandhi S, Takabe K, Ko N, Sanderson M, Hong CC, Bandera EV, Craig DW, Ambrosone CB, Palmer JR, Zheng W, Carpten JD. Nature Genetics. 2025; doi: 10.1038/s41588-025-02322-y.

rMATS-cloud: Large-scale Alternative Splicing Analysis in the Cloud. Adams JI, Kutschera E, Hu Q, Liu CJ, Liu Q, Kadash-Edmondson K, Liu S*, Xing Y*. Genomics Proteomics Bioinformatics. 2025;23(3):qzaf036.

Ten challenges and opportunities in computational immuno-oncology. Bao R, Hutson A, Madabhushi A, Jonsson VD, Rosario SR, Barnholtz-Sloan JS, Fertig EJ, Marathe H, Harris L, Altreuter J, Chen Q, Dignam J, Gentles AJ, Gonzalez-Kozlova E, Gnjatic S, Kim E, Long M, Morgan M, Ruppin E, Valen DV, Zhang H, Vokes N, Meerzaman D*, Liu S*, Van Allen EM*, Xing Y*. Journal for ImmunoTherapy of Cancer. 2024;12(10):e009721.a

Integrated single-cell analysis defines the epigenetic basis of castration-resistant prostate luminal cells. Kirk JS, Wang J, Long M, Rosario S, Tracz A, Ji Y, Kumar R, Liu X, Jamroze A, Singh PK, Puzanov I, Chatta G, Cheng Q, Huang J, Wrana JL, Lovell J, Yu H, Liu S, Shen MM, Liu T, Tang DG. Cell Stem Cell. 2024;31(8):1203-1221.e7.

Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma. Ahluwalia MS, Reardon DA, Abad AP, Curry WT, Wong ET, Figel SA, Mechtler LL, Peereboom DM, Hutson AD, Withers HG, Liu S, Belal AN, Qiu J, Mogensen KM, Dharma SS, Dhawan A, Birkemeier MT, Casucci DM, Ciesielski MJ, Fenstermaker RA. Journal of Clinical Oncology, 2023;41(7):1453-1465.

Understanding Drug Sensitivity and Tackling Resistance in Cancer. Tyner JW*, Haderk F*, Kumaraswamy A*, Baughn LB*, Van Ness BG*, Liu S*, Marathe H*, Alumkal JJ, Bivona TG, Chan KS, Druker BJ, Hutson AD, Nelson PS, Sawyers CL, Willey CD; for the Drug Resistance and Sensitivity Network. Cancer Research 2022;82(8):1448-1460.

Deciphering spatial genomic heterogeneity at a single cell resolution in multiple myeloma. Merz M, Merz AMA, Wang J, Wei L, Hu Q, Hutson N, Rondeau C, Celotto K, Belal A, Alberico R, Block AW, Mohammadpour H, Wallace PK, Tario J, Luce J, Glenn ST, Singh P, Herr MM, Hahn T, Samur M, Munshi N, Liu S*, McCarthy PL*, Hillengass J*. Nature Communications 2022;13(1):807.

Efficacy and Safety of Pembrolizumab in Combination with Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial. Zsiros E, Lynam S, Attwood KM, Wang C, Chilakapati S, Gomez EC, Liu S, Akers S, Lele S, Frederick PJ, Odunsi K. JAMA Oncology 2021;7(1):78-85.

Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s. Oba T, Long MD, Keler T, Marsh HC, Minderman H, Abrams SI*, Liu S*, Ito F. Nature Communications 2020;11(1):5415.

Intron retention is a hallmark and spliceosome represents a therapeutic vulnerability in aggressive prostate cancer. Zhang D, Hu Q, Liu X, Ji Y, Chao HP, Liu Y, Tracz A, Kirk J, Buonamici S, Zhu P, Wang J, Liu S*, Tang DG*. Nature Communications 2020;11(1):2089